REGENXBIO Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REGENXBIO Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $0.00.
- REGENXBIO Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $648.00K, a 111.07% increase year-over-year.
- REGENXBIO Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $0.00.
- REGENXBIO Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $741.00K, a 5.00% decline year-over-year.
- REGENXBIO Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.05M, a 12.01% decline from fiscal 2024.
- REGENXBIO Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.19M, a 34.78% decline from fiscal 2023.
- REGENXBIO Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.83M, a 4.82% increase from fiscal 2022.
- REGENXBIO Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.74M, a 1.47% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $648.00K 10-Q · filed 2026-05-14 | $1.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.05M 10-K · filed 2026-03-05 |
| 2025-09-30 | $741.00K 10-Q · filed 2025-11-06 | $1.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $307.00K 10-Q · filed 2026-05-14 | $1.09M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.19M 10-K · filed 2026-03-05 |
| 2024-09-30 | $780.00K 10-Q · filed 2025-11-06 | $1.19M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.65M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $411.00K 10-Q · filed 2025-05-12 | $1.65M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.83M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.24M 10-Q · filed 2024-11-06 | $1.83M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $1.70M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $583.00K 10-Q · filed 2024-05-08 | $1.70M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.74M 10-K · filed 2025-03-13 |
| 2022-09-30 | $1.12M 10-Q · filed 2023-11-08 | $1.74M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $1.76M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $622.00K 10-Q · filed 2023-05-03 | $1.76M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.77M 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.14M 10-Q · filed 2022-11-03 | $1.77M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $1.82M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $627.00K 10-Q · filed 2022-05-04 | $1.82M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.80M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.19M 10-Q · filed 2021-11-02 | $1.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $1.56M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $607.00K 10-Q · filed 2021-05-05 | $1.56M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.31M 10-K · filed 2022-03-01 |
| 2019-09-30 | $949.00K 10-Q · filed 2020-11-04 | $1.31M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $869.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $365.00K 10-Q · filed 2020-05-07 | $869.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $847.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | $507.00K 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | |
| 2018-03-31 | $342.00K 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $556.00K 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |